INTRODUCTION European Commissioner for Health and Food Safety, Stella Kyriakides, said: “The capacity to perform large-scale testing is key to detecting and slowing down the coronavirus pandemic and is a crucial pre-condition for a gradual return to our normal way of life.’’ is true of Roche, which has already tripled its also come from biotech companies. The production capacities in the United States and American Inovio Pharma targets the month of Europe to respond to needs arising. April, the American Novavax and the German CureVac in May or June, the UK Vaccitech Allover the world,the race for the vaccine this fall,while the Institut Pasteur in France against COVID-19 is indeed going on. The has an advanced candidate with human trials European Commission, for its part, organized planned for this summer. Big Pharma expect an international conference on May 4 which at best entering clinical trials for the end of raised 7,4 billion euros in pledges from around the year for Johnson & Johnson, or the be- 40 governments and organizations to finance ginning of 2021 for Sanofi. For its part, J&J the search for a vaccine against the new embarked on a new challenge by launching coronavirus. The first Covid-19 vaccine to be without delay its production to start clinical tested in humans is the mRNA-1273 of the trials of a vaccine by September. Americanbiotech Moderna whose clinical trial In the world of drug companies, Sanofi has was organized with the NIH (National Institute forged a partnership with its British counter- of Health, an American equivalent of Inserm). part GSK to take advantage of each other’s It took only two months for Moderna - from the strengths to develop an adjuvanted Covid-19 publication ytheChinb ese of the first completevaccine. Sanofi brings to the partnership the genome sequence of the virus - to develop a antigen (the protein that stimulates the body’s vaccine prototype. The next candidates should immune response against the virus), which is